Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future

Frontiers in Pharmacology

Volumn 4 JAN, Issue , 2013, Pages

  Godman, Brian ^a,b,c   Bucsics, Anna ^d   Burkhardt, Thomas ^d   Piessnegger, Jutta ^d   Schmitzer, Manuela ^d   Barbui, Corrado ^e   Raschi, Emanuel ^f   Bennie, Marion ^g,h   Gustafsson, Lars L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d Hauptverband der Österreichischen Sozialversicherungsträger ^*  (Australia)

^e UNIVERSITY OF VERONA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^h INFORMATION SERVICES DIVISION   (United Kingdom)

Author keywords

Antidepressants; Atypical antipsychotics; Austria; Drug utilization studies; Generics; Reforms; Risperidone; Schizophrenia

Indexed keywords

AGOMELATINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; DESVENLAFAXINE; DULOXETINE; GENERIC DRUG; MIRTAZAPINE; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; PALIPERIDONE; QUETIAPINE; REBOXETINE; RISPERIDONE; VENLAFAXINE; ZOTEPINE;

ARTICLE; AUSTRIA; BIPOLAR DISORDER; DEPRESSION; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HUMAN; MENTAL DISEASE; OBSERVATIONAL STUDY; PRESCRIPTION; QUASI EXPERIMENTAL STUDY; SCHIZOPHRENIA;

EID: 84881540504     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00198     Document Type: Article

References (94)

1. Agüera-Ortiz, L., and Ramos Garcia, I. (2006). Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder. Actas Esp. Psiquiatr. 34, 153-161.
2. Alessi-Severini, S., Honcharik, P. L., Simpson, K. D., Eleff, M. K., and Collins, D. M. (2006). Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. J. Clin. Psychiatry 67, 1047-1054.
3. Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., and Stafford, R. S. (2011). Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol. Drug Saf. 20, 177-184.
4. Andretta, M., Ciuna, A., Corbari, L., Cipriani, A., and Barbui, C. (2005). Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol. 40, 72-77.
5. Araszkiewicz, A. A., Szabert, K., Godman, B., Wladysiuk, M., Barbui, C., and Haycox, A. (2008). Generic olanzapine: health authority opportunity or nightmare? Expert. Rev. Pharmacoecon. Outcomes Res. 8, 549-555.
6. Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., et al. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. CD006633.
7. Baldomero, E. B., Ubago, J. G., Cercós, C. L., Ruiloba, J. V., Calvo, C. G., and López, R. P. (2005). Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress. Anxiety 22, 68-76.
8. Bazire, S., and Burton, V. (2004). Generic clozapine in schizophrenia: what is all the fuss about? Pharm. J. 173, 720-721.
9. Bennie, M., Godman, B., Bishop, I., and Campbell, S. (2012). Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert. Rev. Pharmacoecon. Outcomes Res. 12, 125-130.
10. Berkowitz, R. L., Patel, U., Ni, Q., Parks, J. J., and Docherty, J. P. (2012). The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J. Clin. Psychiatry 73, 498-503.
11. Brkicic, L., Voncina, L., Sovic, S., Godman, B., and Relja, M. (2012). Initiatives to improve prescribing efficiency for drugs to treat Parkinson's Disease in Croatia; influence and future directions. Expert. Rev. Pharmacoecon. Outcomes Res. 12, 373-384.
12. Bucsics, A., Godman, B., Burkhardt, T., Schmitzer, M., and Malmström, R. E. (2012). Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Rev. Pharmacoecon Outcomes Res. 12, 809-819.
13. Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746-758.
14. Coma, A., Zara, C., Godman, B., Augusti, A., Diogene, E., Wettermark, B., et al. (2009). Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert. Rev. Pharmacoecon. Outcomes Res. 9, 569-581.
15. Correl, C., and Carbon, M. (2012). Brand vs. generic psychotropic medication. Is one better than the other? Available at: https://www.nwpmd.com/LinkClick.aspx?fileticket=vr6K7kfBUfc%3D&tabid=342
16. Crystal, S., Olfson, M., Huang, C., Pincus, H., and Gerhard, T. (2009). Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff. (Millwood) 28, 770-781.
17. Cymbalta (duloxetine) receives restricted reimbursement. (2010). TLV Decision Duloxetine, Sweden. Available at: http://www.tlv.se/Upload/Genomgangen/100615-tlv-interim-decision-cymbalta.pdf [accessed October 1, 2012]
18. Department of Justice settlement agreement. (2010). Available at: http://www.justice.gov/usao/pae/Pharma-Device/astrazeneca_settlementagreement.pdf [accessed September 18, 2012]
19. Desmarais, J. E., Beauclair, L., and Margolese, H. C. (2011). Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci. Ther. 17, 750-760.
20. Fisk, M., Feeley, J., and Voreacos, D. (2012). J&J Said to Agree to $2.2 Billion Drug Marketing Accord. Available at: http://www.businessweek.com/news/2012-06-11/j-and-j-said-to-pay-2-dot-2-billion-to-end-risperdal-sales-probe [accessed November 18, 2012]
21. Garattini, S., Bertele, V., Godman, B., Haycox, A., Wettermark, B., and Gustafsson, L. L. (2008). Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138.
22. Gardner, D., Baldessarini, R. J., and Waraich, P. (2005). Modern antipsychotic drugs: a critical overview. CMAJ 172, 1703-1711.
23. Garuoliene, K., Godman, B., Gulbinovic, J., Wettermark, B., and Haycox, A. (2011). European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert. Rev. Pharmacoecon. Outcomes Res. 11, 343-349.
24. Godman, B., Bucsics, A., Burkhardt, T., Haycox, A., Seyfried, H., and Wieninger, P. (2008a). Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert. Rev. Pharmacoecon. Outcomes Res. 8, 357-371.
25. Godman, B., Haycox, A., Schwabe, U., Joppi, R., and Garattini, S. (2008b). Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98.
26. Godman, B., Wettermark, B., Hoffman, M., Andersson, K., Haycox, A., and Gustafsson, L. L. (2009a). Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert. Rev. Pharmacoecon. Outcomes Res. 9, 65-83.
27. Godman, B., Schwabe, U., Selke, G., and Wettermark, B. (2009b). Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27, 435-438.
28. Godman, B., Burkhardt, T., Bucsics, A., Wettermark, B., and Wieninger, P. (2009c). Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert. Rev. Pharmacoecon. Outcomes Res. 9, 475-484.
29. Godman, B., Shrank, W., Wettermark, B., Andersen, M., Bishop, I., Burkhardt, T., et al. (2010a). Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494.
30. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010b). Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert. Rev. Pharmacoecon. Outcomes Res. 10, 707-722.
31. Godman, B., Bucsics, A., Burkhardt, T., Schmitzer, M., Wettermark, B., and Wieninger, P. (2010c). Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert. Rev. Pharmacoecon. Outcomes Res. 10, 199-207.
32. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2011a). Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1:141. doi:10.3389/fphar.2010.00141
33. Godman, B., Sakshaug, S., Berg, C., Wettermark, B., and Haycox, A. (2011b). Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert. Rev. Pharmacoecon. Outcomes Res. 11, 121-129.
34. Godman, B., Wettermark, B., Bishop, I., Burkhardt, T., Fürst, J., Garuoliene, K., et al. (2012a). European payer initiatives to reduce prescribing costs through use of generics. GaBi J. 1, 22-27.
35. Godman, B., Malmstrom, R. E., Bennie, M., Sakshaug, S., Burkhardt, T., Campbell, S., et al. (2012b). Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5-16.
36. Godman, B., Abuelkhair, M., Vitry, A., Abdu, S., Bennie, M., Bishop, I., et al. (2012c). Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBi J. 1, 21-35.
37. Godman, B., Bennett, K., Bennie, M., Burkhardt, T., Schmitzer, M., Martin, A., et al. (2012d). Are health authorities and health insurance companies taking full advantage of the availability of generic risperidone; implications for the future? Pharmacoepidemiol. Drug Saf. 21(Suppl. 3), 55-56.
38. Grimshaw, J., Campbell, M., Eccles, M., and Steen, N. (2000). Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam. Pract. 17(Suppl. 1), S11-S16.
39. Gustafsson, L. L., Wettermark, B., Godman, B., Andersén-Karlsson, E., Bergman, U., Hasselström, J., et al. (2011). The "Wise List" - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233.
40. Haddad, P. M., and Sharma, S. G. (2007). Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21, 911-936.
41. Hargreaves, W. A., and Gibson, J. P. (2005). Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 19, 393-410.
42. Healy, D. J., Taylor, S., Goldman, M., Barry, K., Blow, F., and Milner, K. K. (2005). Clinical equivalence of generic clozapine. Community Ment. Health J. 41, 393-398.
43. Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., and Leucht, S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 163, 185-194.
44. Holden, J. (2001). Hawthorne effects and research into clinical practice. J. Eval. Clin. Pract. 7, 65-70.
45. Khorana, N., Maphanta, S., Lohitnavy, O., Srichaiya, A., and Sayasathid, J. (2011). Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers. Int. J. Clin. Pharmacol. Ther. 49, 409-414.
46. Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., and Correll, C. U. (2011). Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry doi:10.1038/mp.2011.143. [Epub ahead of print].
47. Knapp, M., Kanavos, P., King, D., and Yesudian, H. M. (2005). Economic issues in access to medications: schizophrenia treatment in England. Int. J. Law Psychiatry 28, 514-531.
48. Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., et al. (2010). Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. CD006654. doi:10.1002/14651858.CD006654.pub2.
49. Komossa, K., Rummel-Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., et al. (2011). Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. CD006626. doi:10.1002/14651858.CD006626.pub2.
50. Konstantinou, G. (2012). Pragmatic trials: how to adjust for the 'Hawthorne effect'? Thorax 67, 562.
51. Leslie, D., and Rosenheck, R. (2012). Off-label use of antipsychotic medications in Medicaid. Am. J. Manag. Care 18, e109-e117.
52. Leucht, S., Corvers, C., Arbter, D., Engel, R. R., Li, C., and Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
53. Leucht, S., Heres, S., Kissling, W., and Davis, J. M. (2011). Evidence-based pharmacotherapy of schizophrenia. Int. J. Neuropsychopharmacol. 14, 269-284.
54. Leucht, S., Wahlbeck, K., Hamann, J., and Kissling, W. (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581-1589.
55. Lieberman, J. A., and Stroup, T. (2011). Commentary - the NIM H-CAT IE schizophrenia study: what did we learn? Am. J. Psychiatry 168, 770-775.
56. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223.
57. Magnus, A., Carr, V., Mihalopoulos, C., Carter, R., and Vos, T. (2005). Assessing cost-effectiveness of drug interventions for schizophrenia. Aust. N. Z. J. Psychiatry 39, 44-54.
58. Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J. H., Ewing, B., et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306, 1359-1369.
59. Martikainen, J., Saastamoinen, L., Korhonen, M., Enlund, H., and Helin-Salmivaara, A. (2010). Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med. Care 48, 761-766.
60. McGinn, D., Godman, B., Lonsdale, J., Way, R., Wettermark, B., and Haycox, A. (2010). Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK; impact and implications. Expert. Rev. Pharmacoecon. Outcomes Res. 10, 73-85.
61. Meyer-Massetti, C., Vaerini, S., Rätz Bravo, A. E., Meier, C. R., and Guglielmo, B. J. (2011) Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int. J. Clin. Pharm. 33, 806-814.
62. Mirandola, M., Andretta, M., Corbari, L., Sorio, A., Nosè, M., and Barbui, C. (2006). Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol. Drug Saf. 15, 412-420.
63. Mond, J., Morice, R., Owen, C., and Korten, A. (2003). Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust. N. Z. J. Psychiatry 37, 55-61.
64. NICE. (2009). Schizophrenia - Core interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. NICE Clinical Guideline No. 82. Available at: http://www.nice.org.uk/nicemedia/live/11786/43610/43610.pdf
65. NICE. (2008). NICE Implementation Uptake Report: Atypical Antipsychotic Drugs for the Treatment of Schizophrenia. NICE Technology appraisals 43. Available at: http://www.nice.org.uk/media/410/E9/ImplUptakeReportAtypicalAntipsychotics.pdf
66. Norman, C., Zarrinkoub, R., Hasselström, J., Godman, B., Granath, F., and Wettermark, B. (2009). Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326.
67. Parsons, H. M. (1974). What happened at Hawthorne?: New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies. Science 183, 922-932.
68. Paton, C. (2006). Generic clozapine: outcomes after switching. Br. J. Psychiatry 89, 184-185.
69. Poluzzi, E., Raschi, E., Moretti, U., and De Ponti, F. (2009). Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol. Drug Saf. 18, 512-518.
70. R Core Team. (2012). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http://www.R-project.org/ [accessed June 30, 2012]
71. Raja, M. (2011). Clozapine safety, 35 years later. Curr. Drug Saf. 6, 164-184.
72. Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., and Stein, C. M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360, 225-235.
73. Ren, X. S., Qian, S., Lee, A. F., Herz, L., Miller, D. R., and Kazis, L. E. (2006). Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. J. Clin. Pharm. Ther. 31, 57-65.
74. Sermet, C., Andrieu, V., Godman, B., Van Ganse, E., Haycox, A., and Reynier, J. P. (2010). Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24.
75. Spiegel, W., Mlczoch-Czerny, M. T., Jens, R., and Dowrick, C. (2012). Quality circles for pharmacotherapy to modify general practitioners' prescribing behaviour for generic drugs. J. Eval. Clin. Pract. 18, 828-834.
76. Taylor, D. M., Wright, T., and Libretto, S. (2003). Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J. Clin. Psychiatry 64, 589-597.
77. Tiihonen, J., Lönnqvist, J., Wahlbeck, W., Klaukka, T., Niskanen, L., Tanskanen, A., et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620-627.
78. Titier, K., Girodet, P. O., Verdoux, H., Molimard, M., Bégaud, B., and Haverkamp, W. (2005). Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 28, 35-51.
79. Trietsch, J., van der Weijden, T., Verstappen, W., Janknegt, R., Muijrers, P., Winkens, R., et al. (2009). A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: study protocol. Implement. Sci. 4: 6. doi:10.1186/1748-5908-4?6.
80. Tyrer, P., and Kendall, T. (2009). The spurious advance of antipsychotic drug therapy. Lancet 373, 4-5.
81. Valenstein, M., Blow, F. C., Copeland, L. A., McCarthy, J. F., Zeber, J. E., Gillon, L., et al. (2004). Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull. 30, 255-264.
82. Verstappen, W. H. J. M., van der Weijden, T., ter Riet, G., Grimshaw, J., Winkens, R., and Grol, R. (2004). Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering. J. Clin. Epidemiol. 57, 1119-1123.
83. Vieweg, W. V., Wood, M. A., and Fernandez, A. (2009). Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26, 997-1012.
84. Vlahovic-Palcevski, V., Gantumur, M., Radosevic, N., Palcevski, G., and Vander Stichele, R. (2010). Coping with changes in Defined Daily Dose in longitudinal drug consumption databases. Pharm. World Sci. 32, 125-129.
85. Vogler, S., Zimmermann, N., Leopold, C., and de Joncheere, K. (2011). Pharmaceutical policies in European countries in response to the global financial crisis. South. Med. Rev. 4, 22-32.
86. Voncina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., et al. (2011). Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future. Expert. Rev. Pharmacoecon. Outcomes Res. 11, 469-479.
87. Wagner, A. K., Soumerai, S. B., Zhang, F., and Ross-Degnan, D. (2002). Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27, 299-309.
88. Walley, T. (2004). Neuropsychotherapeutics in the UK. What has been the impact of NICE on prescribing? CNS Drugs 18, 1-12.
89. Wettermark, B., Godman, B., Andersson, K., Gustafsson, L. L., Haycox, A., and Bertele, V. (2008). Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550.
90. Wettermark, B., Pehrsson, A., Juhasz-Haverinen, M., Veg, A., Edlert, M., Törnwall-Bergendahl, G., et al. (2009). Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care 17, 179-189.
91. Wladysiuk, M., Araszkiewicz, A., Godman, B., Szabert, K., Barbui, C., and Haycox, A. (2011). Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypicals are available. Appl. Health Econ. Health Policy 9, 101-110.
92. World Health Organization (WHO). (2003). Guidelines for ATC Classification and DDD Assignment 2009. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no [accessed March 5, 2012]
93. World Health Organization (WHO). (2012) Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. (NLM classification: WB 330). Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug
94. Yu-Isenberg, K. S., Fontes, C. L., Wan, G. J., Geissler, E. C., and Harada, A. S. (2004). Acute and continuation treatment adequacy with venlafaxine extended release compared with fluoxetine. Pharmacotherapy 24, 33-40.